Wechselwirkungen · Ivemend
IVEMEND 150 mg powder for solution for infusion. · Abschnitt 4.5 · PDF-Seite 8
HOS-117446 · Präparat HOS-094609
Induction The fosaprepitant 150 mg single dose did not induce CYP3A4 on Days 1 and 4 in the midazolam interaction study. It is anticipated that IVEMEND would cause less or no greater induction of CYP2C9, CYP3A4, and glucuronidation than that caused by the administration of the 3-day oral aprepitant regimen, for which a transient induction with its maximum effect 6-8 days after first aprepitant dose has been observed. The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations. Data are lacking regarding effects on CYP2C8 and CYP2C19. Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered with IVEMEND.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aprepitant (HOS-112506) ethinyl estradiol (HOS-088135) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T14:57:00Z · SHA-256 9e19bc1fa93d788029c9702424aacb9622fe408d4db1dbe0bc9e0ad1d449f179 · Passage a6ffd4af5692deeac0552c1100f062fec5a08edfc14f93a5d49caeba766074f3 · Zeichen 5437–6259 im Abschnitt